77 related articles for article (PubMed ID: 10628332)
21. The effect of butyric acid on adhesion molecule expression by human gingival epithelial cells.
Takigawa S; Sugano N; Nishihara R; Koshi R; Murai M; Yoshinuma N; Ochiai K; Ito K
J Periodontal Res; 2008 Aug; 43(4):386-90. PubMed ID: 18221296
[TBL] [Abstract][Full Text] [Related]
22. Hyaluronic acid as drug delivery for sodium butyrate: improvement of the anti-proliferative activity on a breast-cancer cell line.
Coradini D; Pellizzaro C; Miglierini G; Daidone MG; Perbellini A
Int J Cancer; 1999 May; 81(3):411-6. PubMed ID: 10209956
[TBL] [Abstract][Full Text] [Related]
23. Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in-vitro characterization, ex-vivo and in-vivo studies.
Sanna V; Gavini E; Cossu M; Rassu G; Giunchedi P
J Pharm Pharmacol; 2007 Aug; 59(8):1057-64. PubMed ID: 17725847
[TBL] [Abstract][Full Text] [Related]
24. A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis.
Mann KK; Rephaeli A; Colosimo AL; Diaz Z; Nudelman A; Levovich I; Jing Y; Waxman S; Miller WH
Mol Cancer Res; 2003 Oct; 1(12):903-12. PubMed ID: 14573791
[TBL] [Abstract][Full Text] [Related]
25. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide.
Yang L; Mashima T; Sato S; Mochizuki M; Sakamoto H; Yamori T; Oh-Hara T; Tsuruo T
Cancer Res; 2003 Feb; 63(4):831-7. PubMed ID: 12591734
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of short-chain fatty acids on head and neck squamous carcinoma cells.
Krishna S; Brown N; Faller DV; Spanjaard RA
Laryngoscope; 2002 Apr; 112(4):645-50. PubMed ID: 12150517
[TBL] [Abstract][Full Text] [Related]
27. Sodium butyrate induces growth inhibition and modulates galectin-8 expression in human lung carcinoma cells.
Bidon N; Brichory F; Thomas D; Cavalier A; Caulet-Maugendre S; Bourguet P; Dazord L
Anticancer Res; 2001; 21(2A):1049-55. PubMed ID: 11396139
[TBL] [Abstract][Full Text] [Related]
28. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs.
Hu L; Tang X; Cui F
J Pharm Pharmacol; 2004 Dec; 56(12):1527-35. PubMed ID: 15563759
[TBL] [Abstract][Full Text] [Related]
29. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery.
Paliwal R; Rai S; Vaidya B; Khatri K; Goyal AK; Mishra N; Mehta A; Vyas SP
Nanomedicine; 2009 Jun; 5(2):184-91. PubMed ID: 19095502
[TBL] [Abstract][Full Text] [Related]
30. Adaptation of Clostridium tyrobutyricum for enhanced tolerance to butyric acid in a fibrous-bed bioreactor.
Zhu Y; Yang ST
Biotechnol Prog; 2003; 19(2):365-72. PubMed ID: 12675573
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of butyric acid derivative with xylitol.
Desmet G; Brazier M; Cerutti J; Chany C; Arnould-Guerin ML
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():348-51. PubMed ID: 1820907
[TBL] [Abstract][Full Text] [Related]
32. Apoptosis of U937 human leukemic cells by sodium butyrate is associated with inhibition of telomerase activity.
Choi YH
Int J Oncol; 2006 Nov; 29(5):1207-13. PubMed ID: 17016653
[TBL] [Abstract][Full Text] [Related]
33. Cyclooxygenase-2 expression influences the growth of human large and small cell lung carcinoma lines in athymic mice: impact of an organoselenium compound on growth regulation.
El-Bayoumy K; Rose DP; Papanikolaou N; Leszczynska J; Swamy MV; Rao CV
Int J Oncol; 2002 Mar; 20(3):557-61. PubMed ID: 11836568
[TBL] [Abstract][Full Text] [Related]
34. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
35. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
37. Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: a preclinical study.
Coradini D; Pellizzaro C; Abolafio G; Bosco M; Scarlata I; Cantoni S; Stucchi L; Zorzet S; Turrin C; Sava G; Perbellini A; Daidone MG
Invest New Drugs; 2004 Aug; 22(3):207-17. PubMed ID: 15122068
[TBL] [Abstract][Full Text] [Related]
38. Effects of sodium butyrate on the secretion of beta-2-microglobulin and calcitonin in a human ovarian cancer cell line OC-3-VGH.
Chang CC; Chao KC; Ng HT
Zhonghua Yi Xue Za Zhi (Taipei); 1988 Aug; 42(2):93-8. PubMed ID: 3066455
[No Abstract] [Full Text] [Related]
39. Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts.
Daniel P; Brazier M; Cerutti I; Pieri F; Tardivel I; Desmet G; Baillet J; Chany C
Clin Chim Acta; 1989 May; 181(3):255-63. PubMed ID: 2667816
[TBL] [Abstract][Full Text] [Related]
40. Butyrate effects on growth, morphology, and fibronectin production in PC-3 prostatic carcinoma cells.
Halgunset J; Lamvik T; Espevik T
Prostate; 1988; 12(1):65-77. PubMed ID: 2450342
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
